Respiratory Disease Research: Multi-Modal Biospecimen Approaches

Featured Image Credit: https://phil.cdc.gov/ – Respiratory tissue inflammation (Public Domain)

---

Blood-Based Approaches to Respiratory Disease Investigation

Respiratory diseases including chronic obstructive pulmonary disease, asthma, interstitial lung diseases, and acute respiratory infections affect millions of people across the United States. Understanding what drives these diseases, finding biomarkers, and developing new treatments all require studying systemic and local immune responses together with the inflammatory signals circulating in blood.

Plasma, serum, peripheral blood mononuclear cells, and whole blood offer an accessible window into respiratory disease biology. Inflammatory markers track with disease severity. Immune cell types predict flare-up risk. Gene expression patterns help classify disease subtypes.

Chronic respiratory diseases can take decades to unfold. COPD develops through gradually worsening airflow obstruction. Asthma causes variable airflow limitation punctuated by flare-ups. Pulmonary fibrosis can involve ongoing scarring and declining gas exchange. Each condition follows its own path, which is why longitudinal biospecimen collections that capture molecular and cellular changes over time are so valuable.

From study design through receipt of samples collected under standardized conditions, choosing the right biospecimens enables blood-based respiratory disease research. Researchers at academic pulmonary centers and pharmaceutical companies need high-quality specimens with detailed genomic annotation to support reproducibility and translational relevance.

Chronic Obstructive Pulmonary Disease Biomarkers

COPD affects over 16 million diagnosed people in the United States, with millions more undiagnosed. Chronic bronchitis and emphysema result from smoking, environmental exposures, and genetic factors like alpha-1 antitrypsin deficiency. As airflow becomes progressively limited, systemic inflammation also develops, contributing to cardiovascular disease, osteoporosis, and muscle wasting.

Plasma inflammatory markers including C-reactive protein, fibrinogen, and interleukin-6 are commonly elevated in COPD and can correlate with disease severity and declining lung function. Higher CRP is linked to increased flare-up risk, while fibrinogen has been studied as a prognostic marker for enriching clinical trial populations.

Surfactant protein D, measured in serum, reflects damage to the air sacs and emphysema severity across multiple studies. Club cell secretory protein may decrease in COPD, reflecting damage to the airway lining. These lung-specific proteins complement systemic inflammatory markers, supporting multi-modal biomarker panels that capture both lung-level and body-wide aspects of the disease.

PBMC gene expression profiling has identified COPD-related transcriptional patterns involving inflammatory pathway activation, oxidative stress responses, and epigenetic changes consistent with long-term smoke exposure. Subtypes such as emphysema-predominant versus chronic bronchitis-predominant disease may show distinct molecular profiles that can guide patient stratification in precision medicine studies.

Asthma Inflammation and Biomarker Profiling

Asthma affects over 25 million people in the United States and is marked by airway hyperresponsiveness, inflammation, and variable, often reversible obstruction. Type 2 inflammation, driven by Th2 lymphocytes, eosinophils, and cytokines like IL-4, IL-5, and IL-13, is common in allergic asthma. Non-type 2 inflammation can involve neutrophilic or mixed inflammatory patterns and is often linked to severe disease that doesn’t respond well to treatment.

Serum IgE testing helps identify allergic asthma, including elevated total IgE and allergen-specific IgE responses. IgE-driven mast cell activation causes sudden bronchoconstriction and contributes to long-term airway remodeling through repeated inflammatory cycles.

Eosinophil counts from whole blood are commonly used to estimate flare-up risk and guide biologic therapy selection. Thresholds such as 150–300 eosinophils/μL are frequently used in clinical trial design and everyday practice to identify type 2 inflammation. Context and treatment status can affect how these numbers should be interpreted.

Plasma periostin and other circulating markers have been studied as signs of IL-13-driven epithelial activation. Biomarker performance can vary by assay and population, but these measurements can still add value to subtyping frameworks when combined with clinical features and other immune readouts.

PBMC transcriptomics can distinguish asthma subtypes beyond the simple type 2 versus non-type 2 split. Gene expression patterns may reveal interferon-related signatures, changes in mitochondrial and metabolic activity, or proliferation and activation states — all of which can point toward pathway-targeted treatment approaches.

Essential Quality Specifications for Respiratory Research Biospecimens

When sourcing blood biospecimens for respiratory disease studies, researchers should verify collection context and phenotype definitions to avoid confounding and support reproducibility.

Respiratory Function Documentation

• Spirometry results including FEV1, FVC, and FEV1/FVC ratio
• Bronchodilator reversibility testing differentiating asthma from fixed obstruction
• DLCO measurements for interstitial lung disease and emphysema context
• Six-minute walk distance or other functional capacity measures
• Chest imaging findings (CT or X-ray) describing structural changes
• Disease severity classifications (e.g., GOLD stages, GINA steps)

Clinical Phenotype Characterization

• Symptom scores (CAT for COPD, ACT for asthma) at the time of collection
• Exacerbation history, including frequency and severity over the prior year
• Smoking status and pack-year history (and vaping or biomass exposure where relevant)
• Allergen sensitization profiles in allergic asthma
• Medication regimen including inhaled corticosteroids, biologics, systemic steroids
• Treatment response patterns supporting refractory versus controlled phenotypes
• Comorbidities including cardiovascular disease and metabolic conditions

Sample Collection Variables

• Stable-state versus exacerbation sampling context, which can shift inflammatory profiles
• Medication timing relative to blood draw (e.g., pre- versus post-inhaler)
• Time since last exacerbation influencing baseline biomarker interpretation
• Seasonal effects in allergic asthma, including pollen and viral exposure patterns
• Air quality and environmental triggers at collection
• Recent viral infections that may confound chronic inflammatory measurements

Processing Quality Standards

• Plasma separated within 2 hours to minimize cellular release artifacts
• Serum clotted ~30 minutes at room temperature before centrifugation
• PBMCs isolated within 8 hours maintaining viability targets (commonly >85%)
• Whole blood collected in appropriate tubes when transcriptomics are planned
• Immediate −80°C storage for protein and nucleic acid stability
• Aliquoting strategies limiting freeze–thaw cycles to preserve analyte integrity

Key Research Variables in Respiratory Biospecimen Studies

Investigators studying respiratory biomarkers across diverse U.S. populations should account for disease variety, environmental exposures, and treatment effects. All of these shape immune phenotypes, circulating protein signatures, and how biomarkers change over time.

Disease Heterogeneity Factors

• COPD includes emphysema versus chronic bronchitis phenotypes with distinct biology
• Asthma includes allergic, eosinophilic, neutrophilic, and paucigranulocytic endotypes
• Overlap syndromes (e.g., asthma-COPD overlap) with mixed clinical features
• Rapid versus slow disease progression requiring stratification
• Frequent versus infrequent exacerbators representing distinct pathophysiology

Environmental and Lifestyle Influences

• Geographic location influencing allergen exposures and air quality
• Occupational exposures to dusts, fumes, and chemicals contributing to disease
• Secondhand smoke exposure in never-smokers with respiratory disease
• Climate factors affecting seasonal exacerbation patterns
• Urban versus rural residence correlating with pollution and exposure profiles
• Housing quality affecting mold, dampness, and indoor air triggers

Treatment Impact on Biomarkers

• Inhaled corticosteroids influencing systemic and cellular inflammatory signals
• Biologic therapies altering pathway-specific biomarkers and immune cell distributions
• Systemic corticosteroids during exacerbations profoundly affecting measurements
• Smoking cessation altering inflammatory parameters over time
• Supplemental oxygen and advanced disease affecting metabolic measures

Sanguine Bio’s Comprehensive Respiratory Research Support

Respiratory disease research comes with unique biospecimen challenges, including variability from environmental exposures, flare-up timing, and treatment effects. Sanguine Bio’s direct-to-donor model and expanded donor network provide access to well-characterized patient populations across diverse geographic regions throughout the United States. This supports the environmental and demographic diversity that generalizable findings depend on.

Custom collection services accommodate respiratory-specific needs. We coordinate stable-state versus exacerbation sampling when feasible. We document medication timing, exposure histories, and clinical phenotype definitions to enrich genomic annotation. From study design through receipt of samples, our comprehensive support helps ensure respiratory research holds up and stays consistent downstream.

We also provide access to hard-to-find populations. These include treatment-naive COPD cohorts before long-term therapy begins, severe asthma populations who’ve failed multiple therapies, rare interstitial lung disease subtypes, and longitudinal cohorts that capture natural disease progression. These specialized capabilities support studies that are difficult to run through standard procurement channels.

Respiratory & Metabolic Conditions Biospecimens provides a centralized entry point to explore respiratory-focused biospecimen solutions supporting COPD, asthma, and other lung disease programs.

Ethical Sourcing and Compliance Standards

All respiratory disease biospecimens are ethically sourced under institutional review board approval with informed consent. Participant privacy protections follow HIPAA requirements, with de-identification practices designed to prevent individual identification while preserving research value.

Quality management systems maintain thorough documentation supporting regulatory compliance. Collection protocols follow standard operating procedures. Trained personnel perform venipuncture and processing under validated conditions. Storage and shipping maintain biospecimen integrity and traceability.

Check Our Inventory for available respiratory disease biospecimens or contact us to discuss custom collection services matching your research requirements across geographic regions of the United States.

Advancing Respiratory Medicine Through Blood-Based Research

Blood biospecimens offer a scalable, minimally invasive window into respiratory disease, enabling biomarker discovery, treatment monitoring, and mechanistic research across diverse patient populations. Combining plasma inflammatory markers, serum protein measurements, PBMC immunophenotyping, and whole blood transcriptomics supports the kind of multi-modal molecular profiling that precision respiratory medicine depends on.

From study design through receipt of samples collected under optimized conditions with comprehensive genomic annotation, choosing the right biospecimens speeds up respiratory research. This helps translate discoveries into better outcomes for the millions of people affected by lung disease across the United States.

---

References

1. Agusti A, et al. Systemic effects of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2(4):367-370. https://doi.org/10.1513/pats.200504-026SR
2. Brightling CE, et al. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax. 2005;60(3):193-198. https://doi.org/10.1136/thx.2004.032516
3. Chung KF, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343-373. https://doi.org/10.1183/09031936.00202013
4. Dickens JA, et al. Defining and characterizing bronchiectasis in alpha-1 antitrypsin deficiency. BMC Pulm Med. 2017;17(1):194. https://doi.org/10.1186/s12890-017-0543-0
5. Fingerlin TE, et al. Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet. 2013;45(6):613-620. https://doi.org/10.1038/ng.2609
6. Gibson PG, et al. Heterogeneity of airway inflammation in persistent asthma. Am J Respir Crit Care Med. 2001;164(10 Pt 1):1778-1783. https://doi.org/10.1164/ajrccm.164.10.2011049
7. Haldar P, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med. 2008;178(3):218-224. https://doi.org/10.1164/rccm.200711-1754OC
8. Hilaire RC, et al. Plasma proteomics reveals tissue-specific cell death and mediators of cell-cell interactions in severe COVID-19 patients. Nat Commun. 2020;11(1):6256. https://doi.org/10.1038/s41467-020-20204-y
9. Jatakanon A, et al. Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med. 1999;160(5 Pt 1):1532-1539. https://doi.org/10.1164/ajrccm.160.5.9806170
10. Oczypok EA, et al. Pulmonary receptor for advanced glycation end-products promotes asthma pathogenesis. J Allergy Clin Immunol. 2015;136(3):747-756. https://doi.org/10.1016/j.jaci.2015.03.011
11. Papi A, et al. Asthma. Lancet. 2018;391(10122):783-800. https://doi.org/10.1016/S0140-6736(17)33311-1
12. Sin DD, et al. Biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;173(5):490-491. https://doi.org/10.1164/rccm.200510-1628PP
13. Silkoff PE, et al. ATS/ERS recommendations for measurement of exhaled nitric oxide. Am J Respir Crit Care Med. 2005;171(8):912-930. https://doi.org/10.1164/rccm.200406-710ST
14. Woodruff PG, et al. T-helper type 2-driven inflammation defines subphenotypes of asthma. Am J Respir Crit Care Med. 2009;180(5):388-395. https://doi.org/10.1164/rccm.200903-0392OC
15. Yokokawa T, et al. Elevated exhaled nitric oxide in chronic obstructive pulmonary disease: systematic review and meta-analysis. Resp Res. 2018;19(1):169. https://doi.org/10.1186/s12931-018-0869-x